An Open-label, Multicenter Study of Treatment With Nilotinib in Adult Patients With Imatinib - Resistant or - Intolerant Chronic Myeloid Leukemia in Blast Crisis, Accelerated Phase or Chronic Phase [EXTENSION OF 700013077]
Latest Information Update: 02 Mar 2017
At a glance
- Drugs Nilotinib (Primary)
- Indications Chronic myeloid leukaemia
- Focus Registrational; Therapeutic Use
- Sponsors Novartis Pharmaceuticals
- 26 Feb 2013 New trial record